From: Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients
Clinical parameters | Values | All patients | K-Ras4A expressiona | K-Ras4A proportionb | ||||
---|---|---|---|---|---|---|---|---|
N (%) | High [N (%)] | Low [N (%)] | p-valuec | High [N (%)] | Low [N (%)] | p-value | ||
Age | ≥65 | 276 (53.5) | 137 (26.6) | 139 (26.9) | 1.0 | 141 (27.3) | 135 (26.2) | 0.616 |
< 65 | 221 (42.8) | 110 (21.3) | 111 (21.5) | 107 (20.7) | 114 (22.1) | |||
NAd | 19 (3.7) | 11 (2.1) | 8 (1.6) | 10 (1.9) | 9 (1.9) | |||
Gender | Male | 238 (46.1) | 119 (23.1) | 119 (23.1) | 1.0 | 117 (22.7) | 121 (23.4) | 0.791 |
Female | 278 (53.9) | 139 (26.9) | 139 (26.9) | 141 (27.3) | 137 (26.6) | |||
Smoking history | Yes | 427 (82.8) | 219 (42.4) | 208 (40.3) | 0.299 | 215 (41.7) | 212 (41.1) | 1.0 |
No | 75 (14.5) | 33 (6.4) | 42 (8.1) | 38 (7.4) | 37 (7.2) | |||
NA | 14 (2.7) | 6 (1.2) | 8 (1.6) | 5 (1.0) | 9 (1.7) | |||
KRAS amplificatione | Present | 61 (11.8) | 42 (8.1) | 19 (3.7) | 2.70E-3 | 30 (5.8) | 31 (6.0) | 1.0 |
Absent | 455 (88.2) | 216 (41.9) | 239 (46.3) | 228 (44.2) | 227 (44.0) | |||
KRAS mutations | Present | 148 (28.7) | 110 (21.3) | 38 (7.4) | 4.82E-12 | 101 (19.6) | 47 (9.1) | 2.49E-7 |
Absent | 368 (71.3) | 148 (28.7) | 220 (42.6) | 157 (30.4) | 211 (40.9) | |||
EGFR mutations | Present | 45 (8.7) | 12 (2.3) | 33 (6.4) | 1.81E-3 | 14 (2.7) | 31 (6.0) | 0.0125 |
Absent | 471 (91.3) | 246 (47.7) | 225 (43.6) | 244 (47.3) | 227 (44.0) | |||
Pathological stage | I | 276 (53.5) | 125 (24.2) | 151 (29.3) | 0.0460 | 128 (24.8) | 148 (28.7) | 0.0327 |
II | 122 (23.6) | 66 (12.8) | 56 (10.9) | 58 (11.2) | 64 (12.4) | |||
III | 84 (16.3) | 52 (10.1) | 32 (6.2) | 54 (10.5) | 30 (5.8) | |||
IV | 26 (5.0) | 13 (2.5) | 13 (2.5) | 14 (2.7) | 12 (2.3) | |||
NA | 8 (1.6) | 2 (0.4) | 6 (1.2) | 4 (0.8) | 4 (0.8) |